JAMA

HealthTap Launches AI-Powered Patient Interviews Using GPT-4 to Enhance Telemedicine Visits

Retrieved on: 
Wednesday, September 27, 2023
Telehealth, JAMA, HealthTap, ChatGPT, Research, Language, American Medical Association, Journal, Patient, Medical history, Artificial intelligence, AI, Health, Real-time, Medical device, Nursing, OpenAI

SUNNYVALE, Calif., Sept. 27, 2023 /PRNewswire/ -- HealthTap, a leading virtual healthcare provider delivering quality, affordable primary care across the U.S., today launched a new version of its Dr.A.I.™ feature, a pre-appointment patient interview experience powered GPT-4. The most advanced ChatGPT system from OpenAI, GPT-4 is an artificial intelligence language model capable of human-like conversation. Dr.A.I.™.

Key Points: 
  • The most advanced ChatGPT system from OpenAI, GPT-4 is an artificial intelligence language model capable of human-like conversation.
  • Patient intake interviews powered by GPT-4 means HealthTap doctors can spend more time providing personalized care.
  • "The patient information provided to HealthTap doctors by Dr.A.I.™ lets us be more precise and informed during the doctor visit, said Dr. Geoffrey Rutledge, HealthTap's chief medical officer.
  • "The world wonders how we got along before telemedicine; soon we'll wonder what we did before Dr.A.I.™."

Fight Colorectal Cancer Hosts Congressional Black Caucus Panel to Tackle Disparities and Drive Progress

Retrieved on: 
Thursday, September 21, 2023
VCU Massey Cancer Center, Black and Brown!, Radiation, CRC, Education, ALC, Member of Congress, Detroit Black Community Food Security Network, Health equity, Congressional Black Caucus Foundation, Statistics, Large intestine, African Americans, Associate, Congress, Colorectal cancer, Patient, Cancer, A Call to Action: Women, Religion, Violence, and Power, Diagnosis, Mortality, Health, Conference, JAMA, Dairy, Birth control, Oncology, Black

Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .

Key Points: 
  • Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .
  • Scheduled for September 22, 9-10 am EST, this panel will convene experts, advocates, and policymakers to address the critical disparities in colorectal cancer outcomes among Black Americans.
  • Fight CRC's panel titled 'A Call to Action: Fighting Colorectal Cancer in the Black Community' is co-hosted by Members of Congress, including Representative Donald Payne Jr. (D-NJ) and Representative Nikema Williams (D-GA).
  • Colorectal cancer has a devastating impact on the Black community, with Black Americans being 20% more likely to receive a diagnosis of colorectal cancer compared to their white counterparts.

Ohio Locking Vial Program Designated Best Practice for MAT/MOUD Treatment by Leading Public Health Organization

Retrieved on: 
Tuesday, September 19, 2023
National Association of County and City Health Officials, JAMA, Medicaid, Education, Addiction, Pharmacy, Parent, Opioid use disorder, Data collection, American Medical Association, LPV, Journal, MAT, Patient, Patient safety, Channell, National Association, Safety, Nursing

The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.

Key Points: 
  • The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.
  • The intervention indicated that the use of locking prescription vials (LPVs) reduced one of the common barriers for patient participation in MOUD programs, which include accessibility, stigma, and medication safety.
  • "The intent of the intervention was to see if locking vials could be used as a tool to decrease diversion and increase patient safety and confidence.
  • "As a prescriber, I feel much more confident using the locking prescription vial for the safety of young children and families in my community.

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Retrieved on: 
Sunday, September 10, 2023
Blood pressure, SBP, Male, JAMA, Cleveland Clinic, Obesity, Chronic kidney disease, Heart, Urinary tract infection, Glomerular filtration rate, Hyponatremia, Female, QD, Target, American Medical Association, Hypertension, Plasma protein binding, Aldosterone, Journal, Patient, Disease, Mortality, BMI, Therapy, Safety, Pharmaceutical industry

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and treatment-resistant hypertension (rHTN) were published in the Journal of the American Medical Association (JAMA).

Key Points: 
  • “Despite the multitude of currently available treatments, half of all patients treated for hypertension are not able to reach their blood pressure goal.
  • “We are gratified that JAMA chose to highlight our Target-HTN Phase 2 trial results.
  • "We believe this trial confirms the link between obesity, excess aldosterone production and hypertension.
  • The Target-HTN (NCT05001945) Phase 2 proof-of-concept trial was a randomized, double-blind, placebo-controlled, dose-ranging, multicenter trial conducted in the U.S.

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Retrieved on: 
Sunday, September 10, 2023
JAMA, Obesity, Chronic kidney disease, American Heart Association, AHA, Target, American Medical Association, Hypertension, Journal, BP, Patient, Mercury (element), Pivotal, Body mass index, AOBP, BMI, Therapy, Pharmaceutical industry, Fertilizer

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during a late-breaking science session at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10, and simultaneously published in the Journal of the American Medical Association (JAMA).

Key Points: 
  • The data were presented during a late-breaking science session at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10, and simultaneously published in the Journal of the American Medical Association (JAMA).
  • The reduction in BP was particularly evident among participants with hypertension and concomitant obesity.
  • “The final results from our Target-HTN trial demonstrate lorundrostat had a robust, double-digit reduction in systolic blood pressure with a well-tolerated profile in the intention-to-treat population of individuals with uncontrolled hypertension and resistant hypertension.
  • The presentation at the 2023 AHA Hypertension Scientific Sessions, titled, “Aldosterone Synthase Inhibition with Lorundrostat for Uncontrolled Hypertension: The Target‐HTN Phase 2 Randomized Clinical Trial,” can be accessed on the publications page of the Mineralys corporate website.

Rosemary Mazanet, M.D., PhD. Joins Columbia Care's Board of Directors

Retrieved on: 
Monday, September 11, 2023
Natural Resources, Alternative Medicine, Other Manufacturing, Health, Specialty, Cannabis, Manufacturing, Retail, Columbia University, University of Southern California, Heart, Database, University, Palliative care, Wharton School of the University of Pennsylvania, Journal of Palliative Medicine, Coronavirus Scientific Advisory Board, General partnership, Human, FSE, National Institutes of Health, Bangladesh Technical Education Board, Dana–Farber Cancer Institute, Harvard Medical School, Tablet, Leonard Davis Institute of Health Economics, Journal, RAND Corporation, Clinical research, Internal medicine, Filgrastim, Knowledge, Hospital, FDA, Dana, NEO, NLRB v. Kentucky River Community Care, Inc., Chair, JAMA, Pharmaceutical industry, Management, Amgen, New York University, Brigham

Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.

Key Points: 
  • Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.
  • Since 2013, she has played an integral role of developing groundbreaking form factors specifically for palliative care, such as pressed tablets.
  • I know she will continue to add significant value as a member of our Board of Directors.
  • Congratulations, Rosemary and thank you," said Nicholas Vita, CEO, Columbia Care.

Good Night, Sleep Tight with affron® Natural Melatonin Booster

Retrieved on: 
Wednesday, September 13, 2023
JAMA, Melatonin, Obesity, Headache, Centers for Disease Control and Prevention timeline, Sleep, National Sleep Foundation, Diabetes, Tryptophan, Agriculture, Enzyme, Kynurenine pathway, Person, Trial of the century, American Medical Association, Plasma, Journal, Dizziness, Espinel, Pineal gland, Vivo, Kynurenine, SLU, Water, Menopause, Relaxation, Somnolence, Dietary supplement, Pharmaceutical industry

MADRID, Sept. 13, 2023 /PRNewswire/ -- Results of a new study demonstrate that the standardized affron® saffron extract boosts the body's endogenous production of melatonin. Melatonin—nicknamed the "sleep hormone"—is naturally produced in the body from the dietary amino acid tryptophan. Among other roles, melatonin helps synchronize the sleep–wake cycle and other circadian rhythms and helps adjust for seasonal changes in sleep timing. It has become one of the most commonly used treatment for sleep disorders.

Key Points: 
  • Among other roles, melatonin helps synchronize the sleep–wake cycle and other circadian rhythms and helps adjust for seasonal changes in sleep timing.
  • In summary, the study shows unequivocally that affron has an effect on sleep quality because it stimulates endogenous melatonin production.
  • Insufficient Sleep is defined by The Sleep Foundation as "curtailed sleep that persists for three months or longer," as well as "poor sleep that occurs because of sleep fragmentation or other disruptions."
  • "Better sleep is as much about good sleep as it is about duration of sleep," explains Espinel.

Together, the All-in-One AI Health Assistant, Improves Care for Aging Americans With Voice-Based Mental Health Detection Feature

Retrieved on: 
Wednesday, August 30, 2023
VoIP, Software, Mobile, Wireless, General Health, Telemedicine, Virtual Medicine, Mental Health, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Practice Management, Health, Clifford Whittingham Beers, Blood pressure, Kaiser, JAMA, Obesity, Depression, Face, Google Play, Anxiety, Ageing, Kaiser Family Foundation, Android, Multimedia, MIT, App Store (iOS/iPadOS), American Medical Association, Journal, DSM-IV codes, Patient, Risk, Frustration, Apple, Conditional sentence, Heart rate, MIT Lincoln Laboratory, JAMA Psychiatry, Caregiver, PharmacoEconomics, Nursing, Mobile phone, Medical device

Together , the leading AI-based health assistant, today unveiled its latest groundbreaking feature: Mental Vitals, an innovative mental health detection tool designed to screen for symptoms of depression and anxiety through voice analysis.

Key Points: 
  • Together , the leading AI-based health assistant, today unveiled its latest groundbreaking feature: Mental Vitals, an innovative mental health detection tool designed to screen for symptoms of depression and anxiety through voice analysis.
  • "Our mission with Together is to unify every aspect of health care, from vitals monitoring to mental health detection, into one intuitive platform," said Dr. Renee Dua, founder and chief product officer of Together.
  • According to a Mental Health America 2023 survey report , 54% of adults with a mental illness did not receive treatment.
  • By combining mental health detection, vital measurement, and routine health management, Together can be uniquely effective as an AI-driven patient-centric care coordination and whole-person health platform.

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Retrieved on: 
Friday, August 25, 2023
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Healthcare Reform, Science, Legal, Congressional News, Views, Health, Public Policy, Government, Orphan Drug Act of 1983, Eculizumab, REMS, Central nervous system, Drug development, Vaccination, Prostate cancer, GMG, Infection, Attenuated vaccine, Fever, JAMA, Cancer, Light, Neuromyelitis optica spectrum disorder, Breast, Medicine, NMOSD, IRA, AstraZeneca, Rash, American Medical Association, Neisseria meningitidis, Vomiting, Inflation, ODA, Low-probability-of-intercept radar, Meningococcal vaccine, Patient, Risk, Autoimmune disease, PNH, Immune system, Nausea, Confusion, Inflation Reduction Act of 2022, Rare, Headache, Patient safety, Death, Disease, Pharmaceutical industry, Vaccine

To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).

Key Points: 
  • To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Rare disease and cancer patients depend upon high-risk, low-probability drug development that takes many years to develop and aims for cure.
  • One example is LYNPARZA® (olaparib), a small-molecule cancer medicine approved in 2014 in the US for a small group of late-line ovarian cancer patients.
  • Additional trials added small groups of breast and pancreatic cancer patients, with the most recent indication in prostate cancer approved just this year – nine years later.

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease

Retrieved on: 
Thursday, August 24, 2023
Research, Neurology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, IR, University, PD, Symantec Endpoint Protection, Disease, Anxiety, LD, CI, Urinary tract infection, Parkinson, Trial of the century, Medication, Amneal Pharmaceuticals, Back pain, Dizziness, Patient, Manuscript, Parkinson's disease, Nausea, Dyskinesia, CRL, FDA, JAMA Neurology, NYSE, Treatment, Safety, JAMA, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD).

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD).
  • “Good On” time is defined as the sum of “On” time without dyskinesia and “On” time with non-troublesome dyskinesia.
  • The manuscript titled, “IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease,” was published online on August 14, 2023.
  • Additionally, “Good On” time per dose increased by 1.55 hours with IPX203 compared with immediate-release carbidopa-levodopa (95% CI, 1.37-1.73).